TF ANTAGONIST - NOVO NORDISK AS

Title:

TF ANTAGONIST

Document Type and Number:

WIPO Patent Application WO2004007557

Kind Code:

A3

Abstract:

This invention relates to conjugates of tissue factor (TF) antagonists and a domain that act to elicit a cytotoxic response. The conjugate bind TF with high affinity and specificity but do not initiate blood coagulation. In one embodiment of the present invention the TF antagonist is FVIIa polypeptides chemically inactivated in the active site. In another embodiment the TF antagonist is an antibody against TF. The invention also relates to pharmaceutical compositions comprising the conjugates as well as their use in the prophylaxis or treatment of diseases or disorders related to patho-physiological TF functions including cancer, inflammation, atherosclerosis and ischemia/reperfusion.

Inventors:

STENNICKE HENNING RALF
PETERSEN LARS CHRISTIAN
BJOERN SOEREN E

Application Number:

PCT/DK2003/000480

Publication Date:

April 22, 2004

Filing Date:

July 09, 2003

Export Citation:

Click for automatic bibliography generation Help

Assignee:

NOVO NORDISK AS (DK)

International Classes:

A61K47/48; A61K51/08; C07K5/06; C07K14/705; C07K14/745; A61K38/00; (IPC1-7): C07K19/00; A61K38/04; A61K38/16; A61K38/36; A61K39/395; A61K47/48; C07K7/06; C07K7/08; C07K14/00; C07K14/745; C07K16/36

Domestic Patent References:

WO2001002439A1	2001-01-11
WO2001021661A1	2001-03-29
WO1996012800A1	1996-05-02
WO2000042973A2	2000-07-27

Other References:

DATABASE WPI Section Ch Week 200173, Derwent World Patents Index; Class B04, AN 2001-629603, XP002262305
H. MICHAEL ELLERBY ET AL: "Anti-cancer activity of targeted pro-apoptotic peptides", NATURE MEDICINE, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP002262304

Download PDF:

View/Download PDF PDF Help

Previous Patent: DETECTION OF PRION DISEASE

Next Patent: METHOD FOR OBTAINING MODIFIED POLYSACCHARIDES BY OXIDATION OF HYDROXYL GROUPS